Biomea Fusion

biomeafusion.com

Biomea Fusion is a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with metabolic diseases, obesity, and genetically defined cancers. Utilizing their proprietary FUSION™ System, they aim to create targeted, durable therapies that form permanent bonds with their target proteins, offering advantages over conventional drugs. Founded in 2017, Biomea has developed a robust R&D engine that has produced three novel covalent inhibitor programs currently in preclinical and clinical development, positioning them as innovators in the biopharmaceutical space.